Literature DB >> 59779

Complement-mediated release of histamine from human basophils. II. Biochemical characterization of the reaction.

J A Grant, L Settle, E B Whorton, E Dupree.   

Abstract

Release of histamine from human basophils was induced by activation of complement using zymosan. The histamine-releasing factor resembled C5a on the basis of m.w. (15,000) as well as previous studies showing inactivation by anti-C5. Complement-induced release of histamine was compared with allergic release of histamine which is mediated through appropriate allergens and reaginic IgE. Previously we demonstrated that the former reaction occurred more quickly. Both reactions were inhibited by drugs which increase intracellular concentrations of cAMP3 (theophylline, prostaglandin E1, and histamine) or which mimic the action of cAMP (its dibutyrly derivative). Calcium was required for complement-mediated release of histamine and an increasing response was observed up to physiologic concentrations (2 mM). Magnesium (0 to 1 mM) did not affect the amount of histamine released. Also, glycolysis was probably required for optimal release by complement, since both 2-deoxyglucose and iodoacetamide were inhibitory. When basophils were partly enriched by depletion of neutrophils and eosinophils, the percentage of histamine released by complement was unchanged. Finally, it was shown that activated complement desensitized basophils from responding to a second challenge by the same stimulus. Cross-desensitization was not observed between complement and pollen allergens.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 59779

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Histamine releasing lymphokine: preliminary evidence of membrane receptors on basophils.

Authors:  I C Ezeamuzie; E S Assem
Journal:  Agents Actions       Date:  1985-12

2.  Pharmacological control of human basophil histamine release stimulated by eosinophil granule major basic protein.

Authors:  L L Thomas; L M Zheutlin; G J Gleich
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

3.  Acute inflammatory pulmonary reactions induced by chemotactic factors.

Authors:  U Desai; D L Kreutzer; H Showell; C V Arroyave; P A Ward
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

4.  Inhibition of IgE-mediated histamine release from human leukocytes by a new xanthine derivative, D 4026.

Authors:  B A Petersson; I Svedinger; K Bohlinder
Journal:  Agents Actions       Date:  1980-11

5.  Inflammatory mediators released by complement-derived peptides.

Authors:  H Bult; A G Herman
Journal:  Agents Actions       Date:  1983-08

6.  Mast cell-mediated reactions of host defense and tissue injury: the regulatory role of eosinophil polymorphonuclear leukocytes.

Authors:  E J Goetzl
Journal:  Inflammation       Date:  1977-09       Impact factor: 4.092

7.  Demonstration of inflammatory mediator-induced inflammation and endothelial cell damage in the anterior segment of the eye.

Authors:  F N Rowland; M J Donovan; M Lindsay; W I Weiss; J O'Rourke; D L Kreutzer
Journal:  Am J Pathol       Date:  1983-01       Impact factor: 4.307

8.  Pulmonary injury induced by C3a and C5a anaphylatoxins.

Authors:  N P Stimler; T E Hugli; C M Bloor
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

9.  Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes.

Authors:  Hidetoshi Nitta; Takayuki Shimose; Yasunori Emi; Takahisa Imamura; Koji Ohnishi; Tetsuya Kusumoto; Manabu Yamamoto; Kengo Fukuzawa; Ikuo Takahashi; Hidefumi Higashi; Akihito Tsuji; Yoshito Akagi; Eiji Oki; Yoshihiko Maehara; Hideo Baba
Journal:  Med Oncol       Date:  2016-09-29       Impact factor: 3.064

10.  Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.

Authors:  M M Glovsky; T E Hugli; T Ishizaka; L M Lichtenstein; B W Erickson
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.